Free Trial

Panbela Therapeutics (PBLA) Competitors

Panbela Therapeutics logo
$0.16 0.00 (0.00%)
As of 07/25/2025 02:25 PM Eastern

PBLA vs. PRFX, PCSA, ARAV, GLMD, PWUP, ALZN, ADTX, PTN, JAGX, and ENTO

Should you be buying Panbela Therapeutics stock or one of its competitors? The main competitors of Panbela Therapeutics include PainReform (PRFX), Heatwurx (PCSA), Aravive (ARAV), Galmed Pharmaceuticals (GLMD), PowerUp Acquisition (PWUP), Alzamend Neuro (ALZN), Aditxt (ADTX), Palatin Technologies (PTN), Jaguar Animal Health (JAGX), and Entero Therapeutics (ENTO). These companies are all part of the "pharmaceutical products" industry.

Panbela Therapeutics vs. Its Competitors

PainReform (NASDAQ:PRFX) and Panbela Therapeutics (NASDAQ:PBLA) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, media sentiment, risk, profitability, valuation and earnings.

In the previous week, PainReform had 1 more articles in the media than Panbela Therapeutics. MarketBeat recorded 1 mentions for PainReform and 0 mentions for Panbela Therapeutics. PainReform's average media sentiment score of 1.87 beat Panbela Therapeutics' score of 0.00 indicating that PainReform is being referred to more favorably in the media.

Company Overall Sentiment
PainReform Very Positive
Panbela Therapeutics Neutral

Company Net Margins Return on Equity Return on Assets
PainReformN/A N/A N/A
Panbela Therapeutics N/A N/A -302.61%

PainReform has a beta of 0.56, meaning that its stock price is 44% less volatile than the S&P 500. Comparatively, Panbela Therapeutics has a beta of 1.34, meaning that its stock price is 34% more volatile than the S&P 500.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
PainReform
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00
Panbela Therapeutics
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00

37.3% of PainReform shares are owned by institutional investors. Comparatively, 4.4% of Panbela Therapeutics shares are owned by institutional investors. 34.4% of PainReform shares are owned by company insiders. Comparatively, 0.0% of Panbela Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

PainReform is trading at a lower price-to-earnings ratio than Panbela Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
PainReformN/AN/A-$14.59M-$147.33-0.01
Panbela TherapeuticsN/AN/A-$25.26M-$71.130.00

Summary

PainReform beats Panbela Therapeutics on 6 of the 9 factors compared between the two stocks.

Get Panbela Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for PBLA and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PBLA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

PBLA vs. The Competition

MetricPanbela TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$767K$776.92M$5.69B$9.50B
Dividend YieldN/A4.84%4.58%4.01%
P/E Ratio0.001.4028.1020.05
Price / SalesN/A25.35432.4490.07
Price / CashN/A19.5636.2258.56
Price / Book-0.016.798.665.87
Net Income-$25.26M-$4.32M$3.25B$258.55M
7 Day Performance-1.31%1.15%4.23%3.74%
1 Month Performance-24.81%3.75%10.52%11.75%
1 Year Performance-53.28%9.50%34.41%18.03%

Panbela Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PBLA
Panbela Therapeutics
0.2989 of 5 stars
$0.16
flat
N/A-53.1%$767KN/A0.006
PRFX
PainReform
0.6889 of 5 stars
$1.49
-0.3%
N/A-2.5%$3.00MN/A-0.014
PCSA
Heatwurx
3.0164 of 5 stars
$0.25
+11.3%
$2.00
+700.0%
-85.4%$2.97MN/A-0.0820
ARAV
Aravive
N/A$0.04
flat
N/AN/A$2.95M$9.14M0.0020High Trading Volume
GLMD
Galmed Pharmaceuticals
1.1424 of 5 stars
$1.77
-3.0%
N/A-46.2%$2.92MN/A-0.1120News Coverage
Analyst Upgrade
Gap Up
PWUP
PowerUp Acquisition
N/A$0.36
+0.6%
N/A-95.4%$2.78MN/A0.00N/AGap Up
High Trading Volume
ALZN
Alzamend Neuro
2.6808 of 5 stars
$3.23
-1.1%
$180.00
+5,481.4%
-91.5%$2.58MN/A0.004News Coverage
Upcoming Earnings
Insider Trade
ADTX
Aditxt
N/A$1.19
+0.4%
N/A-100.0%$2.51M$55.32K0.0060
PTN
Palatin Technologies
N/A$0.09
-44.6%
N/AN/A$2.45M$350K-0.0630Gap Down
High Trading Volume
JAGX
Jaguar Animal Health
2.8716 of 5 stars
$2.38
-1.2%
$60.00
+2,421.0%
-93.4%$2.42M$11.55M0.0050
ENTO
Entero Therapeutics
N/A$0.51
+2.5%
N/A-51.0%$2.40MN/A0.009

Related Companies and Tools


This page (NASDAQ:PBLA) was last updated on 7/26/2025 by MarketBeat.com Staff
From Our Partners